Tyra Biosciences (TYRA) insider sells 8,000 shares in planned trade

Rhea-AI Filing Summary

Tyra Biosciences, Inc. reported that an officer serving as Chief Discovery Officer sold 8,000 shares of common stock on 12/12/2025. The transaction was coded as a sale and executed at a weighted average price of $22.6449, with individual sale prices ranging from $22.06 to $23.03.

The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024. Following this transaction, the officer beneficially owns 162,981 shares of Tyra Biosciences common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bensen Daniel

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Discovery Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		S(1)		8,000	D	$22.6449(2)	162,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $22.06 to $23.03. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

	/s/ Ali D. Fawaz, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tyra Biosciences (TYRA) disclose in this filing?

Tyra Biosciences disclosed that its Chief Discovery Officer sold 8,000 shares of the company’s common stock on 12/12/2025 in a reported sale transaction.

What is the role of the reporting person in Tyra Biosciences (TYRA)?

The reporting person is an officer of Tyra Biosciences, serving as the company’s Chief Discovery Officer, as indicated in the relationship section of the filing.

At what price were the TYRA shares sold in this insider transaction?

The 8,000 shares were sold at a weighted average sale price of $22.6449 per share. The filing notes that individual sale prices ranged from $22.06 to $23.03.

How many Tyra Biosciences (TYRA) shares does the officer own after the sale?

After the reported transaction, the officer beneficially owns 162,981 shares of Tyra Biosciences common stock, and this ownership is listed as direct (D).

Was the TYRA stock sale made under a Rule 10b5-1 trading plan?

Yes. The filing explains that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.

Is the reported Tyra Biosciences (TYRA) ownership direct or indirect?

The filing shows that the 162,981 shares beneficially owned following the transaction are held with an ownership form of Direct (D), with no indirect ownership listed.